It looks like your browser is not up to date.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Eloxx Pharmaceuticals Inc (ELOX) USD0.01

Sell:$2.08 Buy:$2.10 Change: $0.02 (0.96%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $0.02 (0.96%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $0.02 (0.96%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing ribonucleic acid (RNA)-modulating drug candidates, which are designed to be eukaryotic ribosomal selective glycosides (ERSG). It is developing its drug candidates for treating rare and ultra-rare premature stop codon diseases. ELX-02 is its lead investigational drug product candidate. ELX-02 is a small molecule drug candidate designed to restore production of full-length functional proteins. ELX-02 is in the early stages of clinical development for systemic administration for cystic fibrosis and cystinosis. Its preclinical candidate pool consists of a library of novel ERSG drug candidates identified based on read-through potential and cytoplasmic ribosomal selectivity.

Contact details

950 Winter St
United States
+1 (858) 9090749

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$180.90 million
Shares in issue:
86.15 million
United States
US dollar

Key personnel

  • Sumit Aggarwal
    President, Chief Executive Officer, Director
  • Gary Rakers
    Principal Financial and Accounting Officer, Executive Director - Finance and Accounting, Corporate Controller, Treasurer
  • Daniel Geffken
    Interim Chief Financial Officer
  • Neil Belloff
    Chief Operating Officer, General Counsel, Corporate Secretary
  • Vijay Modur
    Head - Research and Development

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.